TEST ID ACRN Acylcarnitines, Quantitative, Plasma
Reporting Name
Acylcarnitines, Quantitative, PSpecimen Type
PlasmaNecessary Information
1. Patient's age is required.
2. Include family history, clinical condition (asymptomatic or acute episode), diet, and drug therapy information.
Specimen Required
Patient Preparation: Collect specimen just prior to a scheduled meal or feeding.
Collection Container/Tube:
Preferred: Green top (sodium heparin)
Acceptable: Lavender top (EDTA) or green top (lithium heparin)
Submission Container/Tube: Plastic vial
Specimen Volume: 0.1 mL
Collection Instructions: Centrifuge and aliquot plasma into plastic vial.
Specimen Minimum Volume
0.04 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma | Frozen (preferred) | 92 days | |
Refrigerated | 64 days | ||
Ambient | 8 days |
Method Name
Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Reference Values
≤7 days (nmol/mL) |
8 days-7 years (nmol/mL) |
≥8 years (nmol/mL) |
|
Acetylcarnitine, C2 |
2.14-15.89 |
2.00-27.57 |
2.00-17.83 |
Acrylylcarnitine, C3:1 |
<0.04 |
<0.05 |
<0.07 |
Propionylcarnitine, C3 |
<0.55 |
<1.78 |
<0.88 |
Formiminoglutamate, FIGLU |
<0.43 |
<0.08 |
<0.14 |
Iso-/Butyrylcarnitine, C4 |
<0.46 |
<1.06 |
<0.83 |
Tiglylcarnitine, C5:1 |
<0.05 |
<0.09 |
<0.11 |
Isovaleryl-/2-Methylbutyrylcarn C5 |
<0.38 |
<0.63 |
<0.51 |
3-OH-iso-/butyrylcarnitine, C4-OH |
<0.13 |
<0.51 |
<0.18 |
Hexenoylcarnitine, C6:1 |
<0.12 |
<0.10 |
<0.15 |
Hexanoylcarnitine, C6 |
<0.14 |
<0.23 |
<0.17 |
3-OH-isovalerylcarnitine, C5-OH |
<0.08 |
<0.12 |
<0.10 |
Benzoylcarnitine |
<0.13 |
<0.07 |
<0.10 |
Heptanoylcarnitine, C7 |
<0.05 |
<0.05 |
<0.06 |
3-OH-hexanoylcarnitine, C6-OH |
<0.08 |
<0.19 |
<0.09 |
Phenylacetylcarnitine |
<0.15 |
<0.22 |
<0.29 |
Salicylcarnitine |
<0.08 |
<0.09 |
<0.09 |
Octenoylcarnitine, C8:1 |
<0.48 |
<0.91 |
<0.88 |
Octanoylcarnitine, C8 |
<0.19 |
<0.45 |
<0.78 |
Malonylcarnitine, C3-DC |
<0.09 |
<0.14 |
<0.26 |
Decadienoylcarnitine, C10:2 |
<0.11 |
<0.12 |
<0.26 |
Decenoylcarnitine, C10:1 |
<0.25 |
<0.46 |
<0.47 |
Decanoylcarnitine, C10 |
<0.27 |
<0.91 |
<0.88 |
Methylmalonyl-/succinylcarn, C4-DC |
<0.05 |
<0.05 |
<0.05 |
3-OH-decenoylcarnitine, C10:1-OH |
<0.12 |
<0.12 |
<0.13 |
Glutarylcarnitine, C5-DC |
<0.06 |
<0.10 |
<0.11 |
Dodecenoylcarnitine, C12:1 |
<0.19 |
<0.37 |
<0.35 |
Dodecanoylcarnitine, C12 |
<0.18 |
<0.35 |
<0.26 |
3-Methylglutarylcarnitine, C6-DC |
<0.28 |
<0.21 |
<0.43 |
3-OH-dodecenoylcarnitine, C12:1-OH |
<0.11 |
<0.10 |
<0.13 |
3-OH-dodecanoylcarnitine, C12-OH |
<0.06 |
<0.09 |
<0.08 |
Tetradecadienoylcarnitine, C14:2 |
<0.09 |
<0.13 |
<0.18 |
Tetradecenoylcarnitine, C14:1 |
<0.16 |
<0.35 |
<0.24 |
Tetradecanoylcarnitine, C14 |
<0.11 |
<0.15 |
<0.12 |
Octanedioylcarnitine, C8-DC |
<0.25 |
<0.19 |
<0.19 |
3-OH-tetradecenoylcarnitine C14:1OH |
<0.06 |
<0.18 |
<0.13 |
3-OH-tetradecanoylcarnitine, C14-OH |
<0.04 |
<0.05 |
<0.08 |
Hexadecenoylcarnitine, C16:1 |
<0.15 |
<0.21 |
<0.10 |
Hexadecanoylcarnitine, C16 |
<0.36 |
<0.52 |
<0.23 |
3-OH-hexadecenoylcarnitine,C16:1-OH |
<0.78 |
<0.36 |
<0.06 |
3-OH-hexadecanoylcarnitine, C16-OH |
<0.10 |
<0.07 |
<0.06 |
Octadecadienoylcarnitine, C18:2 |
<0.12 |
<0.31 |
<0.24 |
Octadecenoylcarnitine, C18:1 |
<0.25 |
<0.45 |
<0.39 |
Octadecanoylcarnitine, C18 |
<0.10 |
<0.12 |
<0.14 |
Dodecanedioylcarnitine, C12-DC |
<0.10 |
<0.04 |
<0.04 |
3-OH-octadecadienoylcarn, C18:2-OH |
<0.04 |
<0.06 |
<0.06 |
3-OH-octadecenoylcarnitine C18:1-OH |
<0.03 |
<0.04 |
<0.06 |
3-OH-octadecanoylcarnitine, C18-OH |
<0.03 |
<0.05 |
<0.03 |
Day(s) Performed
Monday through Friday
Report Available
2 to 5 daysSpecimen Retention Time
1 monthPerforming Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
82017
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
Useful For
Diagnosis of fatty acid oxidation disorders and several organic acidurias using plasma specimens
Evaluating treatment during follow-up of patients with fatty acid beta-oxidation disorders and several organic acidurias